tiprankstipranks
Theravance Biopharma (TBPH)
NASDAQ:TBPH

Theravance Biopharma (TBPH) Financial Statements

310 Followers

Theravance Biopharma Financial Overview

Theravance Biopharma's market cap is currently ―. The company's EPS TTM is $-0.86; its P/E ratio is -10.18; Theravance Biopharma is scheduled to report earnings on July 31, 2024, and the estimated EPS forecast is $-0.21. See an overview of income statement, balance sheet, and cash flow financials.
Mar 24Dec 23Sep 23Jun 23Mar 23
Income Statement-
Total Revenue$ 14.50M$ 17.57M$ 15.69M$ 13.75M$ 10.41M
Gross Profit$ 14.50M$ 17.57M$ 15.69M$ 13.75M$ 10.42M
EBIT$ -9.77M-$ -6.97M$ -13.62M$ -21.93M
EBITDA$ -8.59M---$ -20.95M
Net Income Common Stockholders$ -11.66M$ -8.51M$ -8.95M$ -21.91M$ -29.51M
Balance Sheet-
Cash, Cash Equivalents and Short-Term Investments$ 99.97M$ 102.43M$ 134.00M$ 167.45M$ 241.26M
Total Assets$ 371.31M$ 382.00M$ 413.59M$ 446.63M$ 538.55M
Total Debt$ 47.90M$ 49.16M$ 50.83M$ 51.68M$ 51.19M
Net Debt$ -52.07M$ -53.27M$ -83.17M$ -115.77M$ -190.07M
Total Liabilities$ 166.44M$ 169.00M$ 167.46M$ 166.47M$ 167.99M
Stockholders Equity$ 204.87M$ 213.00M$ 246.13M$ 280.16M$ 370.56M
Cash Flow-
Free Cash Flow$ -1.11M---$ -11.95M
Operating Cash Flow$ -1.02M$ -854.00K$ -2.49M$ -12.44M$ -11.22M
Investing Cash Flow$ 17.03M$ -677.00K$ -21.00K$ 11.05M$ -43.05M
Financing Cash Flow$ -1.72M$ -30.61M$ -31.40M$ -80.68M$ -56.24M
Currency in USD

Theravance Biopharma Earnings and Revenue History

Theravance Biopharma Debt to Assets

Theravance Biopharma Cash Flow

Theravance Biopharma Forecast EPS vs Actual EPS

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis